JP2018502115A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502115A5 JP2018502115A5 JP2017534937A JP2017534937A JP2018502115A5 JP 2018502115 A5 JP2018502115 A5 JP 2018502115A5 JP 2017534937 A JP2017534937 A JP 2017534937A JP 2017534937 A JP2017534937 A JP 2017534937A JP 2018502115 A5 JP2018502115 A5 JP 2018502115A5
- Authority
- JP
- Japan
- Prior art keywords
- medium
- concentration
- present
- cells
- substituents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002609 medium Substances 0.000 claims description 150
- 238000000034 method Methods 0.000 claims description 143
- 125000001424 substituent group Chemical group 0.000 claims description 121
- 210000004027 cell Anatomy 0.000 claims description 111
- -1 1H-benzoimidazolyl Chemical group 0.000 claims description 67
- 210000000822 natural killer cell Anatomy 0.000 claims description 53
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 34
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 34
- 108090001005 Interleukin-6 Proteins 0.000 claims description 34
- 108010002586 Interleukin-7 Proteins 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 239000003055 low molecular weight heparin Substances 0.000 claims description 28
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 28
- 238000012258 culturing Methods 0.000 claims description 25
- 102000003812 Interleukin-15 Human genes 0.000 claims description 21
- 108090000172 Interleukin-15 Proteins 0.000 claims description 21
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 108700014844 flt3 ligand Proteins 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims description 16
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 12
- 108010002350 Interleukin-2 Proteins 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 210000000130 stem cell Anatomy 0.000 claims description 12
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 10
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 10
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000001483 mobilizing effect Effects 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 claims description 8
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
- 230000003013 cytotoxicity Effects 0.000 claims description 8
- 231100000135 cytotoxicity Toxicity 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- IEJAIKPHVAPFSS-UHFFFAOYSA-N 9h-pyrimido[4,5-b]indole Chemical group N1C=NC=C2C3=CC=CC=C3N=C21 IEJAIKPHVAPFSS-UHFFFAOYSA-N 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 210000002662 placental hematopoietic stem cell Anatomy 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims description 4
- 230000003169 placental effect Effects 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 4
- 125000005955 1H-indazolyl group Chemical group 0.000 claims description 3
- LKTNEXPODAWWFM-UHFFFAOYSA-N 2-methyl-N-[2-methyl-4-(2-methylphenyl)azophenyl]-3-pyrazolecarboxamide Chemical compound CC1=CC=CC=C1N=NC(C=C1C)=CC=C1NC(=O)C1=CC=NN1C LKTNEXPODAWWFM-UHFFFAOYSA-N 0.000 claims description 3
- 101100172469 Escherichia coli (strain K12) envZ gene Proteins 0.000 claims description 3
- 101150077103 TPO gene Proteins 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- BGFHMYJZJZLMHW-UHFFFAOYSA-N 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol Chemical group N1=C(C=2C3=CC=CC=C3SC=2)N=C2N(C(C)C)C=NC2=C1NCCC1=CC=C(O)C=C1 BGFHMYJZJZLMHW-UHFFFAOYSA-N 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 208000006402 Ductal Carcinoma Diseases 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 102000036693 Thrombopoietin Human genes 0.000 claims description 2
- 108010041111 Thrombopoietin Proteins 0.000 claims description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical group C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 2
- 201000011186 acute T cell leukemia Diseases 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 101150009274 nhr-1 gene Proteins 0.000 claims description 2
- 125000004274 oxetan-2-yl group Chemical group [H]C1([H])OC([H])(*)C1([H])[H] 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940016667 resveratrol Drugs 0.000 claims description 2
- 235000021283 resveratrol Nutrition 0.000 claims description 2
- 201000006845 reticulosarcoma Diseases 0.000 claims description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 23
- 238000010186 staining Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 4
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 3
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098560P | 2014-12-31 | 2014-12-31 | |
| US62/098,560 | 2014-12-31 | ||
| PCT/US2015/068055 WO2016109661A1 (en) | 2014-12-31 | 2015-12-30 | Natural killer cells and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213684A Division JP2021072786A (ja) | 2014-12-31 | 2020-12-23 | ナチュラルキラー細胞及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018502115A JP2018502115A (ja) | 2018-01-25 |
| JP2018502115A5 true JP2018502115A5 (enExample) | 2019-02-21 |
Family
ID=56285039
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534937A Pending JP2018502115A (ja) | 2014-12-31 | 2015-12-30 | ナチュラルキラー細胞及びその使用 |
| JP2020213684A Pending JP2021072786A (ja) | 2014-12-31 | 2020-12-23 | ナチュラルキラー細胞及びその使用 |
| JP2022176993A Pending JP2023022037A (ja) | 2014-12-31 | 2022-11-04 | ナチュラルキラー細胞及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213684A Pending JP2021072786A (ja) | 2014-12-31 | 2020-12-23 | ナチュラルキラー細胞及びその使用 |
| JP2022176993A Pending JP2023022037A (ja) | 2014-12-31 | 2022-11-04 | ナチュラルキラー細胞及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20180008637A1 (enExample) |
| EP (1) | EP3240552A4 (enExample) |
| JP (3) | JP2018502115A (enExample) |
| KR (2) | KR20170098938A (enExample) |
| CN (1) | CN107405364A (enExample) |
| AU (2) | AU2015374055A1 (enExample) |
| BR (1) | BR112017014269A2 (enExample) |
| CA (1) | CA2972662A1 (enExample) |
| EA (1) | EA201791443A1 (enExample) |
| IL (1) | IL253248A0 (enExample) |
| NZ (1) | NZ733213A (enExample) |
| WO (1) | WO2016109661A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| ES2980858T3 (es) * | 2015-09-15 | 2024-10-03 | Stichting Radboud Univ Medisch Centrum | Método mejorado para la expansión ex vivo de HSPC CD34+ en células NK usando un antagonista del receptor de aril hidrocarburos |
| MY201637A (en) * | 2015-10-15 | 2024-03-06 | Celularity Inc | Natural killer cells and ilc3 cells and uses thereof |
| WO2018085775A1 (en) * | 2016-11-04 | 2018-05-11 | Ohio State Innovation Foundation | Methods and compositions for treating multiple myeloma and increasing antibody dependent cell cytotoxicity by targeting the aryl hydrocarbon receptor |
| MX2019007840A (es) * | 2016-12-30 | 2020-08-03 | Celularity Inc | Celulas asesinas naturales modificadas geneticamente. |
| IL269553B2 (en) | 2017-03-27 | 2025-10-01 | Nat Univ Singapore | Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| BR112020003116A2 (pt) * | 2017-08-17 | 2020-08-04 | Ikena Oncology, Inc. | inibidores de ahr e usos dos mesmos |
| KR102167548B1 (ko) * | 2017-09-21 | 2020-10-19 | 한국생명공학연구원 | 자연살해세포의 제조방법 및 그의 용도 |
| WO2019059713A2 (ko) * | 2017-09-21 | 2019-03-28 | 한국생명공학연구원 | 자연살해세포의 제조방법 및 그의 용도 |
| US12258381B2 (en) | 2018-02-09 | 2025-03-25 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019161494A1 (en) | 2018-02-20 | 2019-08-29 | Universite De Montreal | Expansion of nk and dc cells in vivo mediating immune response |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| JP2021525066A (ja) | 2018-05-30 | 2021-09-24 | グリコステム セラピューティクス ベスローテン フェンノートシャップ | Ｃａｒ ｎｋ細胞 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| WO2020070070A1 (en) * | 2018-10-01 | 2020-04-09 | Universiteit Gent | Accelerated human hematopoietic stem cell differentiation towards mature natural killer cells with enhanced antibody-dependent cytotoxic activity |
| CN109294985B (zh) * | 2018-10-25 | 2022-02-18 | 江苏普瑞康生物医药科技有限公司 | 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法 |
| US20230028680A1 (en) * | 2018-11-30 | 2023-01-26 | Celularity Inc. | Expansion of natural killer cells and ilc3 cells with novel aromatic compounds |
| CN113383070A (zh) * | 2018-12-21 | 2021-09-10 | 加拿大干细胞技术公司 | 用于分化天然杀伤细胞的培养基和方法 |
| CN113811315A (zh) * | 2019-01-18 | 2021-12-17 | 育世博生物科技股份有限公司 | 一种新颖的cd16阳性自然杀手细胞及一种培养cd16阳性自然杀手细胞的方法 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| WO2020197318A1 (ko) * | 2019-03-28 | 2020-10-01 | 한국생명공학연구원 | Car 유전자가 도입된 nk 세포의 제조방법 및 그의 용도 |
| CN110079529A (zh) * | 2019-04-28 | 2019-08-02 | 成都美杰赛尔生物科技有限公司 | 用于靶向敲除人NKG2A/KLRC1基因的sgRNA、表达载体、试剂盒及其用途 |
| US20220265712A1 (en) * | 2019-06-14 | 2022-08-25 | Celularity Inc. | Populations of natural killer cells for treating cancers |
| CN113652393B (zh) * | 2020-05-12 | 2023-08-15 | 内蒙古大学 | 一种提高牛胚胎干细胞多能性的方法 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| CN113046314B (zh) * | 2021-03-30 | 2022-11-25 | 中国科学技术大学 | 一种人脐血或骨髓造血干细胞体外诱导扩增蜕膜样自然杀伤细胞的方法 |
| CN113337466B (zh) * | 2021-07-13 | 2023-03-24 | 杭州原生生物科技有限公司 | 一种无血清nk分化培养基及其制备方法 |
| CN115381959A (zh) * | 2022-09-30 | 2022-11-25 | 上海纳米技术及应用国家工程研究中心有限公司 | 一种治疗肝癌的联合用药 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230096132A (ko) * | 2010-07-13 | 2023-06-29 | 셀룰래리티 인코포레이티드 | 천연 킬러 세포의 생성 방법 |
| JP6250556B2 (ja) * | 2012-01-27 | 2017-12-20 | ユニヴェルスィテ・ドゥ・モントリオール | ピリミド［４，５−ｂ］インドール誘導体及び造血幹細胞の増殖におけるその使用 |
| CA2864283C (en) * | 2012-02-08 | 2020-11-03 | Jan Spanholtz | Ex vivo nk cell differentiation from cd34+ hematopoietic cells |
| US9175266B2 (en) * | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
| US20150225697A1 (en) * | 2012-08-13 | 2015-08-13 | Anthrogenesis Corporation | Natural killer cells and uses thereof |
-
2015
- 2015-12-30 JP JP2017534937A patent/JP2018502115A/ja active Pending
- 2015-12-30 KR KR1020177021038A patent/KR20170098938A/ko not_active Ceased
- 2015-12-30 EA EA201791443A patent/EA201791443A1/ru unknown
- 2015-12-30 BR BR112017014269A patent/BR112017014269A2/pt not_active Application Discontinuation
- 2015-12-30 AU AU2015374055A patent/AU2015374055A1/en not_active Abandoned
- 2015-12-30 NZ NZ733213A patent/NZ733213A/en not_active IP Right Cessation
- 2015-12-30 KR KR1020237033327A patent/KR20230146101A/ko not_active Ceased
- 2015-12-30 CN CN201580077231.5A patent/CN107405364A/zh active Pending
- 2015-12-30 US US15/541,004 patent/US20180008637A1/en not_active Abandoned
- 2015-12-30 WO PCT/US2015/068055 patent/WO2016109661A1/en not_active Ceased
- 2015-12-30 EP EP15876255.9A patent/EP3240552A4/en not_active Withdrawn
- 2015-12-30 CA CA2972662A patent/CA2972662A1/en active Pending
-
2017
- 2017-06-29 IL IL253248A patent/IL253248A0/en unknown
-
2020
- 2020-05-18 US US16/876,979 patent/US20200330516A1/en not_active Abandoned
- 2020-12-23 JP JP2020213684A patent/JP2021072786A/ja active Pending
-
2021
- 2021-12-06 AU AU2021282387A patent/AU2021282387A1/en not_active Abandoned
-
2022
- 2022-11-04 JP JP2022176993A patent/JP2023022037A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502115A5 (enExample) | ||
| JP2023171766A5 (enExample) | ||
| Klopp et al. | Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? | |
| Saito et al. | Adoptive transfer of CD8+ T cells generated from induced pluripotent stem cells triggers regressions of large tumors along with immunological memory | |
| Crompton et al. | Uncoupling T‐cell expansion from effector differentiation in cell‐based immunotherapy | |
| JP7616817B2 (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| Pang et al. | TGF-β signaling in myeloid cells is required for tumor metastasis | |
| Solís-Martínez et al. | Regulation of immunophenotype modulation of monocytes-macrophages from M1 into M2 by prostate cancer cell-culture supernatant via transcription factor STAT3 | |
| JP2023171766A (ja) | ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用 | |
| JP2015504902A5 (enExample) | ||
| RU2015108761A (ru) | Природные клетки-киллеры и их применение | |
| KR20170098938A (ko) | 천연 킬러 세포 및 그의 용도 | |
| Wang et al. | A small-molecule/cytokine combination enhances hematopoietic stem cell proliferation via inhibition of cell differentiation | |
| Domogala et al. | Natural killer cell immunotherapy: from bench to bedside | |
| CN113454207A (zh) | 用新型芳香族化合物扩增自然杀伤细胞和ilc3细胞 | |
| KR20190005964A (ko) | 천연 킬러 세포를 이용한 급성 골수성 백혈병 및 다발성 골수종의 치료 방법 | |
| Shaim et al. | Cord blood: a promising source of allogeneic natural killer cells for immunotherapy | |
| JP2014176353A (ja) | ヒト造血幹細胞を増幅させるための組成物及び方法 | |
| Sayegh et al. | Application of natural killer immunotherapy in blood cancers and solid tumors | |
| Radtke et al. | Human multipotent hematopoietic progenitor cell expansion is neither supported in endothelial and endothelial/mesenchymal co-cultures nor in NSG mice | |
| Kumar et al. | Multiplexed iPSC platform for advanced NK cell immunotherapies | |
| JPWO2020113182A5 (enExample) | ||
| Nakajima‐Takagi et al. | Manipulation of hematopoietic stem cells for regenerative medicine | |
| Park et al. | Enhancement of proliferation of human umbilical cord blood–derived CD34+ hematopoietic stem cells by a combination of hyper-interleukin-6 and small molecules | |
| US20200289566A1 (en) | Compositions for improving car-t cell functionality and use thereof |